← SynDRA

GILTERITINIB

SynDRA canonical compound SYN0038050 — structure-anchored drug synonym record

All known targets

• FLT3
• AXL
• ROS1
• LTK
• RET
• NTRK1
• MERTK
• ALK
• PHKG2
• MAPK9
• RAN
• RABL3

Mechanisms of action (all sources)

• FLT3 INHIBITOR
• Tyrosine-protein kinase receptor FLT3 inhibitor
• AXL INHIBITOR
• Tyrosine-protein kinase receptor UFO inhibitor
• ALK INHIBITOR
• ROS1 INHIBITOR
• LTK INHIBITOR
• MERTK INHIBITOR
• NTRK1 INHIBITOR
• RET INHIBITOR

Drug classes

• Tyrosine Kinase Inhibitors

ATC classes

• L01E · PROTEIN KINASE INHIBITORS

Cross-references

• PubChem CID: 49803313
• ChEMBL: CHEMBL3301622
• DrugBank: DB12141
• ChEBI: CHEBI:145372
• KEGG: D10709
• RxNorm: 2105806
• PDB: C6F
• Wikipedia: Gilteritinib
• TTD: D04KZY

Synonyms

• gilteritinib fumarate
• xospata
• ASP2215
• ASP-2215
• UNII-66D92MGC8M
• 66D92MGC8M
• Gilteritinib [USAN:INN]
• Gilteritinib(ASP2215)
• Gilteritinib (USAN/INN)
• Gilteritinib (ASP2215)
• Gilteritinib (ASP-2215)
• SCHEMBL282229
• GTPL8708
• MolPort-038-934-933
• BDBM144315
• C29H44N8O3
• 3694AH
• s7754
• AKOS030234455
• ZINC113476229
• DB12141
• CS-3885
• KS-0000064E
• AS-35199
• ASP 2215
• Xospata
• 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide
• Gilteritinib HCl
• 2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-
• 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide
• 6-ethyl-3-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
• 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
• gilteritinibum
• 2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-
• C6F
• GILTERITINIB [MI]
• GILTERITINIB [INN]
• GILTERITINIB [USAN]

Reported adverse events

• Alanine aminotransferase increased
• Aspartate aminotransferase increased
• Constipation
• Cough
• Dizziness
• Fatigue
• Myalgia
• Nausea
• Posterior reversible encephalopathy syndrome
• Abdominal pain
• Febrile neutropenia
• Headache